Am J Clin Exp Immunol 2024;13(4):142-164
www.ajcei.us /ISSN:2164-7712/AJCEI0155121

Review Article

Advance in the mechanism and clinical research of myalgia in long COVID

Xiuyun Zhai[1*], Weijun Wu[1*], Siliang Zeng[2], Yun Miao[1,3]

[1]Department of Rehabilitation, Shanghai General Hospital, Shanghai Jiaotong University, No. 100, Haining Road, Shanghai 200080, China; [2]Department of Rehabilitation Therapy, School of Health, Shanghai Normal University Tianhua College, No. 1661, North Shengxin Road, Shanghai 201815, China; [3]Department of Rehabilitation, School of International Medical Technology, Shanghai Sanda University, No. 2727, Jinhai Road, Shanghai 201209, China. [*]Equal contributors.

Received December 26, 2023; Accepted July 18, 2024; Epub August 25, 2024; Published August 30, 2024

Abstract: As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, mortality rates of coronavirus disease 2019 (COVID-19) have significantly decreased. However, a variable proportion of patients exhibit persistent prolonged symptoms of COVID-19 infection (long COVID). This virus primarily attacks respiratory system, but numerous individuals complain persistent skeletal muscle pain or worsening pre-existing muscle pain post COVID-19, which severely affects the quality of life and recovery. Currently, there is limited research on the skeletal muscle pain in long COVID. In this brief review, we review potential pathological mechanisms of skeletal muscle pain in long COVID, and summarize the various auxiliary examinations and treatments for skeletal muscle pain in long COVID. We consider abnormal activation of inflammatory response, myopathy, and neurological damages as pivotal pathological mechanisms of skeletal muscle pain in long COVID. A comprehensive examination is significantly important in order to work out effective treatment plans and relieve skeletal muscle pain. So far, rehabilitation interventions for myalgia in long COVID contain but are not limited to drug, nutraceutical therapy, gut microbiome-targeted therapy, interventional therapy and strength training. Our study provides a potential mechanism reference for clinical researches, highlighting the importance of comprehensive approach and management of skeletal muscle pain in long COVID. The relief of skeletal muscle pain will accelerate rehabilitation process, improve activities of daily living and enhance the quality of life, promoting individuals return to society with profound significance.

Keywords: SARS-CoV-2, COVID-19, long COVID, skeletal muscle pain, myalgia

Introduction

COVID-19, a disease widely spread and regarded as a public health emergency, is caused by SARS-CoV-2. COVID-19 has severely threatened people's normal life and contributed massive damage to global health and economy. In addition to respiratory system, SARS-CoV-2 causes multiorgan dysfunctions including damages to neurological [1, 2], musculoskeletal, cardiovascular [3], gastrointestinal, skin, and other systems [4, 5]. COVID-19 has been demonstrated to manifest as a broad clinical spectrum, ranging from asymptomatic to severe or fatal, with up to 15%-20% of patients requiring hospitalization [6, 7]. Independent studies suggest that 35.8% to 62.5% of SARS-CoV-2 patients during acute phase experience skeletal muscle pain, indicating skeletal muscle injury occurs during the acute phase of the infection [8-12].

To our knowledge, persistent symptoms may exist after infection with many viruses and bacteria [13-15]. COVID-19 is no exception. A significant number of COVID-19 patients experience long-term symptoms, known as long COVID [16-18]. There is no unified definition for long COVID by far, but we have compiled several literature sources to define it as symptoms and signs that persist for more than four weeks after acute COVID-19 in order to early identification. With the long-term prevalence of COVID-19, global scholars have conducted several prospective follow-up studies on long COVID and found that persistent symptoms after COVID-19 include cough, dyspnea, chest/throat pain,

https://doi.org/10.62347/TXVO6284



Figure 1. Common locations of skeletal muscle pain in long COVID. Common locations of chronic skeletal muscle pain include the spine, shoulders, and limbs. Spinal pain is more common, with the highest incidence of skeletal muscle pain occurring in the lumbar muscles of the spine. Created with BioRender.com.

headache, musculoskeletal symptoms (myalgia, arthralgias, fatigue), abdominal symptoms, cognitive symptom, olfactory or gustatory dysfunction, sleep disorders, anxiety or depression [19-21]. The majority of these symptoms extend from the acute phase of COVID-19.

Constituting 40% of body weight, the skeletal muscle composed of myofibers is a indispensable part of human body and plays a prominent role in energy metabolism, mechanical movement [22] and respiratory ventilation [23, 24]. Therefore, our attention has been drawn to persistent skeletal muscle pain. Studies indicated that 42%-65%, 21%, 15%, 5%-41%, 6%, 15-43% and 6%-38% of COVID-19 patients still had skeletal muscle pain at post discharge [25-28], five [29], eight weeks [26], three [27, 30-33], six months [32, 34-37] and one year [37-42] after discharge, respectively. The follow-up population was mainly hospitalized patients, but there are still a few follow-up data of non-hospitalized COVID-19 patients with mild symptoms. Myalgia was one of the main symptoms during 1.5 to 6 months of follow-up in 451 non-hospitalized COVID-19 patients [6]. 55% of 100 non-hospitalized patients with neurological symptoms still complained skeletal muscle pain at 5 months of follow-up [43]. Furthermore, premorbid skeletal muscle pain has been shown to confer an increased susceptibility to long-COVID, with a prevalence of 38% at 7 months after COVID-19 infection [44]. We consider that the heterogeneity of populations, preexisting comorbidities, history of skeletal muscle pain, disease severity and treatment regimens are meaningful interpretations of discrepancy in the prevalence of skeletal muscle pain in long COVID.

With respect to sex predisposition to myalgia in long COVID, there is no consensus. Albeit musculoskeletal pain exhibits a female predominance after 6 months, 8 months and 1 or 2 years following acute SARS-CoV-2 infection [28, 32, 37, 45, 46], some studies have reported opposite results that suggest no associations with sex 5 months post infection while female is susceptible to skeletal muscle pain during acute COVID-19 [47].

Locations where chronic skeletal muscle pain appear include spine, shoulders, and limbs. The spine is not only the most prevalent musculoskeletal pain position experienced by patients before COVID-19 but also the persistent pain region complained by patients infected with COVID-19 (**Figure 1**) [44]. The most common region of spine pain in post-acute COVID-19 patients was the back (30.4%) [48]. This phenomenon may be due to widespread expression of coronavirus-related factors and receptors in human dorsal root ganglia (DRG) at lumbar and thoracic levels [49]. In an extension cohort study of hospitalized COVID-19 survivors at 6 months, regional muscle pain was distributed in the lower leg, arm, and shoulder girdle [32].

Based on a review of current researches, we believe that myalgia in long COVID may be primarily associated with abnormal activation of inflammatory response, myopathy, and neurological damages (**Figure 2**). Persistent pain after COVID-19 has demonstrated to decrease the quality of life, ultimately resulting in psychological disorders such as anxiety and depression [31, 50-53]. Chronic pain is a complex and distressing issue, and patients must receive comprehensive examizations and effective and



Figure 2. Schematic illustration of the main underlying pathophysiological mechanisms of skeletal muscle pain in long COVID. A. Upon entry into the body through the respiratory tract, SARS-CoV-2 can activate the innate and adaptive immune responses of the organism, with excessive activation of the inflammatory system leading to a cytokine storm. After SARS-CoV-2 infection, respiratory ventilation and gas exchange dysfunction can lead to hyoxemia, inducing skeletal muscle mitochondrial oxidative stress. If the damaged mtDNA is not repaired in time, the skeletal muscle may ultimately face outcomes such as apoptosis, necrosis, and aging, further promoting the progression of inflammation. B. Cross-reactivity between SARS-CoV-2 and muscle antigens induce myopathy. C. Inflammatory cytokines such as IL-6 and immune-active substances such as IFN-α, IFN-β contribute to nociceptor hyperexcitability in muscle injury. Besides, SARS-CoV-2-induced small fiber neuropathy participate in persistent skeletal muscle pain. Created with BioRender.com.

sustained treatments to control their long-term pain to an acceptable level [54].

Literature search methods

Curiously, research on skeletal muscle pain in long COVID mainly focuses on the description of incidence and clinical characteristics, with limited studies on its pathogenesis. We conducted a comprehensive literature search using three electronic databases including Web of Science, PubMed, and Google Scholar, without a date limit. The last literature search was performed on 20th December 2023. The search terms were set to [("Post-acute COVID-19 syndrome" OR "Post-Acute COVID-19 Syndromes" OR "Long-COVID" OR "Long-COVID syndrome" OR "Long-COVID-19" OR "Long-haul" OR "Long-hauls" OR "Long-haul COVID" OR "Long Haul COVID-19" OR "Post-Acute Sequelae of SARS-CoV-2 Infection" OR "Post-acute sequelae of SARS-CoV-2" OR "Long Post-COVID symptoms" OR "persistent Post-COVID symptoms" OR "Post-COVID-19 syndrome" OR "Post-COVID Conditions" OR "Post-COVID Condition" OR "post COVID" OR "post COVID-19" OR "chronic COVID" OR "PASC" OR "PACS" OR "persisting COVID" OR "COVID complications" OR "SARS-CoV-2 complications") AND ("myalgia" OR "myositis" OR "myopathy" OR "Muscle Pain" OR "Muscle Soreness" OR "Muscle Tenderness")]. The search results were screened by title, abstract and full text, and reference lists were checked for further articles meeting the search criteria. The types of literature obtained included original research articles, case reports,

case series, reviews, comments and letters to the editor. We excluded studies in non-English language and literatures that were not associated with or did not mention myalgia in long COVID, finally 211 articles were included in this review. Due to the limited number of studies, clinical heterogeneity and methodologic diversity on myalgias in long COVID, we did not make a meta-analysis. Therefore, we have integrated this information and present it in a narrative form in each section of this review for comprehensive discussion, looking forward to providing a reference for clinical work.

Potential pathological mechanisms of myalgia in long COVID

The relationship between SARS-CoV-2 infection and skeletal muscle pain in long COVID

Skeletal muscle pain is a common and nonspecific symptom in long COVID and its diagnosis in terms of etiology is a particularly challenging job in clinical practice. The relationship between SARS-CoV-2 infection and myalgia remains a comparatively under-researched field. However, it is a generally acknowledged fact that the pathogenesis of SARS-CoV-2 involves binding to angiotensin-converting enzyme 2 (ACE2) receptor on the host cell surface, resulting in the proteolysis of transmembrane protease serine 2 (TMPRSS2) protein and the activation of coronavirus S protein fusion signal peptide (S2 subunit), which facilitates the fusion between SARS-CoV-2 and cell membranes [55, 56]. Hence, viral RNA replicates in human cytoplasm [57-59]. Since ACE2 receptors express in various tissues including human skeletal muscles, it is postulated that SARS-CoV-2 may directly infect skeletal muscle cells via ACE2 [11, 60, 61], activate immune cells and cause direct and immune-mediated indirect muscle impairment.

Diaphragm is the main skeletal muscle of respiration. SARS-CoV-2 viral RNA were found in the autopsy diaphragm specimens of 4 patients (15.4%) who had been critically ill with COVID-19 [62]. However, Aschman discovered that inflammation was more pronounced in subacute and chronic stages, and while some muscle specimens showed SARS-CoV-2 RNA, it could be attributed to viral RNA in circulation rather than true myocyte infection. Moreover, upregulation of major histocompatibility-complex (MHC) class I and II antigens on the muscle membrane indicates that skeletal muscle is involved in the immune response against SARS-CoV-2 [3]. Evidence of inflammation or immune-mediated myopathy was revealed in skeletal muscle autopsies of 35 patients who died due to SARS-CoV-2 infection, but no direct invasion of SARS-CoV-2 into skeletal muscle was observed, suggesting that skeletal muscle damage was secondary to inflammatory or immune response [63]. The above findings were based on deceased COVID-19 patients, and extrapolation to mild disease course is likely to provoke debates. Fortunately, although muscle biopsies are rarely performed, there are a few case reports. For instance, Manzano performed a biopsy of the left deltoid muscle of a patient with COVID-19 infection and myopathy. They reported that no SARS-CoV-2 virus in the muscle and no membrane attack complex deposition, but abnormal expression of MHC class I antigens and myxovirus resistance protein A (MxA) on muscle fibers and capillaries, indicating that his SARS-CoV-2 myopathy may have been due to type I interferonopathy [64]. Type I interferons activate the MNK-eIF4E signaling pathway through DRG-specific receptors (IFNR) and drive the plasticity of nociceptors, promoting pain and worsening existing pain status [65]. In conclusion, we speculate that persistent skeletal muscle pain in long COVID may be associated with inflammation, myopathy, and neurological damages rather than direct viral infection of skeletal muscle. Of course, we sincerely appeal to long COVID patients with persistent skeletal muscle pain to engage in muscle biopsy to further validate this hypothesis.

Abnormal activation of inflammatory response

Skeletal muscle, with abundant content of mitochondria, occupies an important position in energy metabolism. There are two populations of mitochondria in skeletal muscle, subsarcolemmal mitochondria (SSM) and interfibrillar mitochondria (IFM), respectively. The former one generates greater amounts of reactive oxygen species (ROS). Mitochondrial stress still exists in asymptomatic or mild COVID-19 patients 40 days after infection, with an increase in peroxiredoxin 3 (PRDX3) and a decrease in carbamoyl phosphate synthase 1 (CPS1), indicating a long-term disruption of anti-inflammatory and stress response [66].

Table 1. Common hematological indicators of myalgia in long COVID

Characteristic	Indicators
Blood Routine	WBC, Lymphocytes, Neutrophil, Platelet count, Hemoglobin
Inflammation marker	CRP, ESR, PCT
Cytokines	IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12, IL-17, TNF-α, IFN-γ
Muscle Metabolism	LDH, CK, CK-MB, hs-Troponin-T
Autoantibodies	Anti-PM/Scl, anti-Jo1, anti-Mi-2, anti-TIF1-γ, anti-MDA5
Blood gas analysis	PH, PO2, $HCO3^-$
Coagulation	INR, Fibrinogen, D-dimer, aPTT, PT, TT
Clinical Chemistry	Albumin, ALP, ALT, AST, Creatinine, Taurine, electrolyte

Abbreviations: WBC = White Blood Cells; CRP = C-Reactive Protein; ESR = Erythrocyte Sedimentation Rate; PCT = Procalcitonin; IL = interleukin; TNF-α = Tumor Necrosis Factor-alpha; IFN-γ = interferon-gamma; LDH = Lactate Dehydrogenase; CK = Creatine Kinase; CK-MB = Creatine Kinase Myocardial Band; hs-Troponin-T = high sensitive Troponin-T; PM/Scl = Polymyositis Scleroderma; TIF1-γ = Transcription Intermediary Factor 1-gamma; MDA5 = Melanoma Differentiation Associated Gene 5; INR = International Normalized Ratio; aPTT = activated Partial Thromboplastin Time; PT = Prothrombin Time; TT = Thrombin Time; ALP = Alkaline Phosphatase; ALT = Alanine Transaminase; AST = Aspartate Transaminase.

Compared with twelve patients without long-term symptoms, citrate synthase, peroxisome proliferator-activated receptor-γ coactivator (PGC)1α in vastus lateralis biopsies and JO2 for mitochondrial complex II were significantly lower in eleven patients with PASC. This study indicates impaired mitochondrial biogenesis and reduced mitochondrial function in myalgia patients. What's more, pro-fusion protein levels (OPA1) were lower while proteins involved in fission [pDRP1 (Ser616), and FIS1] were higher in myalgia patients. The pro-fission shift in mitochondrial dynamics activated mitophagy to optimizes the function of mitochondria and muscles [67]. However, this conclusion will be more convincing if enlarging number of patients and excluding mood disorders and nervous system diseases [68]. Pulmonary function still reduced in 6 months after hospital discharge due to SARS-CoV-2 infection [69]. Moreover, patients who had recovered from COVID-19 for 11 months without cardiopulmonary disease exhibited impaired oxygen extraction and ventilation inefficiency during exercise, suggesting that skeletal muscle pain in long COVID may be associated with mitochondrial dysfunction due to low oxygen supply [70, 71]. Mitochondrial oxidative stress can also lead to an increase in mitochondrial DNA (mtDNA) damage. If the limited efficiency of the mtDNA repair mechanisms cannot ensure the integrity of mtDNA, it will bring about adverse outcomes such as apoptosis, pyroptosis, necrosis, or senescence of skeletal muscle cell, further aggravating the body's inflammatory response [72-74]. In summary, it is highly likely that inflammation triggered by SARS-CoV-2 infection is related to skeletal muscle pain in long COVID.

Immunological dysfunction was reported in mild-to-moderate SARS-CoV-2 infection individuals at 8 months. It mainly manifested as highly activated innate immune cells such as cytotoxic $CD8^+$ T cells, lacked naive T and B cells and elevated expression of inflammatory mediators such as type I IFN (IFN-β), type III IFN (IFN-λ1) [75]. A cross-sectional study following mild COVID-19 cases for 3 months found the values of serum CRP, fibrinogen and neutrophil count were slightly but significantly higher in patients with Post-COVID syndrome (PCS). This study demonstrated that SARS-CoV-2 not only trigger elevated cytokines but also cause the release of damage-associated molecular patterns (DAMPs) to contribute to low-grade inflammation (LGI) in long COVID. Myalgia is one of the most reported symptoms of LGI and can be interpreted by higher fibrinogen levels [76, 77].

The uncontrolled replication of viruses and systematic inflammatory responses, typically referred to cytokine storms, are caused by hyperactivation of numerous cells, including T cells, B cells, dendritic cells, nature killer (NK) cells, macrophages, neutrophils, monocytes, and tissue cells such as epithelial and endothelial cells, which release large amounts of pro-inflammatory cytokines and soluble inflammatory markers (**Table 1**), hence furtherly sustaining abnormal systemic inflammation [78]. Among molecules increased in cytokine storm serum, interleukin-1β (IL-1β), IL-6, IL-12, IL-17,

tumour necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) are crucial [79, 80]. $CD4^+$ T cells differentiate into various T helper cells after being activated by antigen presenting cells (APCs) [81, 82]. Cytokines secreted by Th1 and Th17 cells can mediate muscle damage by directly inducing muscle fiber proteolysis and reducing protein synthesis [83-88]. On the other hand, cytokines can directly act on muscle fibers to promote the synthesis of soluble pro-inflammatory mediators, thus contributing to the sustained presence of the inflammatory response [89, 90]. Besides, long COVID may be associated with mast cell activation syndrome (MCAS) [91]. MACS is characteristic of hyperactivation of mast cells and increase in mast cell mediator levels [92]. The markers of mast cell activation mainly include tryptase, histamine metabolites, prostaglandin D2 or metabolites, leukotriene E4 and chemokines such as IL-1β and IL-6 [93, 94]. However, the relationship between myalgia in the long COVID and MACS are scarcely reported.

Myalgia is usually due to generalized inflammation and cytokine response, with IL-6 playing a predominant role. IL-6 not only provokes acute muscle hyperalgesia but also results in chronic latent hyperalgesia [95]. Specifically, IL-6 activates peripheral nociceptors by upregulating TNFα and IL-1β expression, promoting immune cell infiltration, activating multiple signaling pathways [96]. There are reports of applying tocilizumab to critically ill COVID-19 patients in clinical practice. Tocilizumab is a humanised anti-IL-6 receptor monoclonal antibody of the IgG1 subtype that has been recommended to treat rheumatoid arthritis and other chronic inflammatory diseases, effectively inhibiting signal transduction pathway by blocking IL-6 receptor interactions [97]. Considering that the cytokine storm induced by COVID-19 manifests as an increase in cytokines such as IL-6, TNF-α and IL-1β, the pathophysiology of skeletal muscle pain also involve these cytokines. Therefore, it seems reasonable to link SARS-CoV-2 infection with muscle pain through the inflammatory response. Moreover, MicroRNAs, small noncoding RNAs that regulate genes, are reported to invovle in pathogenic mechanisms of chronic pain in the long COVID population. Differentially expressed miRNAs which included miR-21-5p, miR-29a, b, c-3p miR-92a, b-3p, miR-92b-5p, miR-126-3p, miR-150-5p, miR-155-5p, miR-200a, c-3p, miR-320a, b, c, d, e-3p, and miR-451a were associated with IL-6/STAT3 proinflammatory axis [98].

The literature has well documented that sustained presence of hyperinflammatory state in long COVID contributes to the reduction in muscle protein synthesis and increased protein degradation [99]. In addition, the decreased physical function and lack of enough physical activity, as well as inadequate nutrient intake because of olfactory or gustatory dysfunction, are beneficial to the development of sarcopenia [22]. Therefore, we should be alert to sarcopenia when individuals complain sustained skeletal muscle pain after acute COVID-19 infection. Low muscle strength, evaluated using grip strength, is considered the main parameter of sarcopenia. According to the latest EWGSOP2 consensus definition, male subjects aged 65 or above with handgrip strength < 27 kg and female subjects < 16 kg are considered to suffer from sarcopenia. Cut-off values for subjects in the lower age groups are identified by age- and sex-matched healthy controls from the community (Lookup 7+ sample) [100, 101]. A prospective observational study indicated that COVID-19 survivors experiencing high muscle mass loss during actue infection can not fully recover muscle health 6 months post discharge, whereas the low muscle loss group did. High and low muscle loss group were stratified according to the magnitude of loss in vastus lateralis muscle by B-mode ultrasound. Furthermore, high muscle loss group showed greater prevalence of myalgia at 6 months after discharge [102].

Myopathy

Agergaard conducted neurophysiological examinations on 20 patients who were suspected of neurological disorders and infected with COVID-19 8 months ago, but found no signs of neurological pathology. However, quantitative electromyography suggested myopathy in 11 cases, with 8 of these myopathy patients experiencing muscle pain [103]. This discovery provides a strong support for the hypothesis that myopathy may be a significant cause of skeletal muscle pain in long COVID. Terms commonly used to describe myopathy events include muscle pain, virus-induced muscle damage, myopathy, myositis, and rhabdomyolysis. To date,

there is no consensus on the nomenclature of myopathies, therefore the confusion of terminology may lead to inadequate attention and delayed diagnosis of muscle injury events [104].

Idiopathic inflammatory myopathies (IIMs) are a group of heterogeneous autoimmune muscle diseases, which have been classified into the following main types based on their unique clinical and pathological features and potential immunopathogenic mechanisms: polymyositis (PM) [105, 106], dermatomyositis (DM), inclusion body myositis (IBM), and immune-mediated necrotizing myopathy (IMNM). A recent cross-sectional study studies have documented 24% patients experienced myopathy post-COVID-19 infection while the prevalence of myopathy is 7.8% in control group [107].

Common autoantibodies of myopathy are listed in **Table 1**. The relationship between COVID-19 infection and IIMs has remained elusive. Megremis identified six antigenic epitopes highly homologous to human SARS-CoV-2 in the serum of 20 patients with TIF1-γ (TRIM33)-positive dermatomyositis, three of which were highly specific to SARS-CoV-2, suggesting that immune system abnormalities after COVID-19 infection may contribute to the development of IIMs [108]. Muscle biopsy from a 51-year-old Chilean-American man suggested acute necrotizing myositis 3 months after COVID-19 infection and his symptoms was alleviated when treated with Prednisolone and Azathioprine [109]. Muscle biopsies of 16 long COVID patients who complained of fatigue, muscle pain, or weakness lasting for up to 14 months, among whom 44% had persistent muscle pain, 75% had myopathy on electromyography, revealed that all patients had histological changes and 62% patients had mitochondrial changes comprising cytochrome c oxidase deficiency, subsarcolemmal accumulation, and/or abnormal cristae [110], implying that persistent skeletal muscle pain is not ascribed to a single factor and the possibility of COVID-19-related myopathy caused by hyperinflammation cannot be ruled out. Myalgia is not only a common symptom in patients with long COVID, but also may be associated with systemic autoimmune rheumatic diseases (SARDs) and fibromyalgia (FM). The key point to distinguish them lies in history inquiry, clinical and hematological examination. Patients suffered from SARD always exhibit strongly positive disease-specific autoantibodies [111] and skin rashes while FM is not accompanied with muscle weakness and increase of CK [112].

Although rare, SARS-CoV-2-related rhabdomyolysis is a serious complication of myositis that should be taken into account [113-116]. The characteristic features of rhabdomyolysis are elevation of CK (typically > 10 times the upper limit of normal), creatinine elevation, and usually brown urine or myoglobinuria. The primary causes are myotoxic anti-COVID-19 drugs, severe electrolyte imbalances, ischemia, prolonged bed rest, and immune-mediated injury [117, 118]. Myotoxic drugs that rhabdomyolysis patients take include azithromycin, hydroxychloroquine, paclitaxel, propofol, imatinib, piperacillin, meropenem, hydrochlorothiazide, and acetaminophen. 74% of patients with COVID-19 and coexisting rhabdomyolysis during the acute phase reported muscle pain. Diagnosis of rhabdomyolysis during the COVID-19 pandemic has been challenging because fatigue, muscle pain, elevated liver enzymes and lactate dehydrogenase levels are common manifestations in COVID-19 and rhabdomyolysis. Hence, we should keep rhabdomyolysis in mind when encounter with skeletal muscle pain during the acute phase of COVID-19 [104, 119]. Importantly, after recovery from rhabdomyolysis, patients are supposed to experience all-round neurological examinations, electromyography, and even muscle biopsy or genetic testing in case of overlooking persistent muscle damage. Patient with carnitine palmitoyltransferase II (CPT II) deficiency suffered from rhabdomyolysis after administering COVID-19 vaccine [120]. Besides, COVID-19 infection was regarded as a fatal triggering factor for patient affected with long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency [121]. Therefore, proper caution should be exercised when delivering vaccinations (including the COVID-19 vaccination) or infecting with SARS-CoV-2 in population with an underlying neuromuscular disorder.

Neurological damages

COVID-19 is primarily a respiratory disease, but it can affect multisystem including the nervous system, with nearly 34% of SARS-CoV-2 infect-

ed individuals diagnosed with neurological or psychiatric illnesses 6 months after acute COVID-19 [122]. Neurological manifestations in long COVID can be classified into two categories: central nervous system (fatigue, headache, sleep disorders, cognitive impairment, emotional/mood disorders, dizziness, dysautonomia), peripheral nervous system manifestations (muscle weakness, myalgias, hyposmia, hypogeusia, hearing loss, sensorimotor deficits) [2, 123-130].

It is still unclear whether the virus can directly infect the nervous system. No virus invasion is supported by many observations [131-133]. For example, Suh did not detect direct viral invasion of psoas muscle or femoral nerve of deceased COVID-19 patients, suggesting that the damages to these tissues may be mediated by inflammatory or immune response [63]. On the other hand, many studies found direct SARS-CoV-2 viral invasion of cerebrospinal fluid and frontal lobe tissue [134-137]. Matschke reported detecting SARS-CoV-2 viral proteins in the IX and X cranial nerves of the medulla oblongata during autopsy, suggesting that the persistent taste impairment commonly seen in COVID-19 may be related to SARS-CoV-2's tropism for gustatory neurons, which provide a pathway to brainstem. This study also found the presence of SARS-CoV-2 RNA and protein in the brain of COVID-19 patients, indicating that SARS-CoV-2 could invade the central nervous system, but its presence does not correlate with the severity of neurological pathology [133]. Therefore, it is interpreted that SARS-CoV-2 invasion of brain can take place but not in every case. Besides, central nervous system damage and neurological symptoms may be caused by other factors such as cytokine storms, neuroimmune activation, rather than the virus directly infecting the central nervous system. This point of view is consistent with the mechanisms underlying COVID-related headaches. Tolebeyan proposes that COVID-related headaches which resemble migraines and other types of headaches primarily caused by inflammation, which activate nociceptive neurons via cytokines and chemokines [138]. Sun also suggests that in addition to systemic inflammation, changes in the immune system play a role in the development of chronic pain following COVID-19 [54].

Skeletal muscles connected to bones not only produce movement through contraction under the control of motor neurons in the central and peripheral nervous system [139], but also transmit signals to the central nervous system via receptors. Myalgia, a nonspecific descriptor, encompasses a series of abnormal muscle sensations such as cramping, stiffness, and tenderness. However, the common feature of all these sensations is the activation of pain receptors in skeletal muscle. Hyperexcitability and hyperactivity of nociceptive neurons are the basis for pain [140]. Type I IFNs promote nociceptor sensitization by activating mitogen-activated protein kinase interacting kinase (MNK) eukaryotic initiation factor (eIF) 4E signaling axis in DRG neurons when viral infection [65, 141]. Furtherly, eIF4E phosphorylation contribute to elevated interleukin (IL)-1β and tumor necrosis factor (TNF)-α [142] and translational control of brain-derived neurotrophic factor (BDNF) expression [143]. The nature of pain turns to chronic muscle pain when structural changes generate.

Bocci firstly combined neurophysiological assessments, quantitative electromyography (qEMG), and sympathetic skin response (SSR) to investigate myalgia and fatigue symptoms in long COVID patients. Surprisingly, these symptoms are not related to myopathy, but to the autonomic nervous system [144]. Besides, a retrospective study reported that the skin biopsy results of 13 patients who suffered from new-onset painful paresthesias within 2 months after acute SARS-CoV-2 infection. Six out of 13 patients were diagnosed as small fiber neuropathy (SFN) on skin biopsy, including two patients exhibited autonomic dysfunction by autonomic function testing (AFT). This finding suggests that SFN may underlie pain in long COVID [145]. Additionlly, a considerable amount of COVID-19 patients complained of paroxysmal diffuse burning and itching sensation in the skin. After excluding drugs, diabetes, neurological diseases, or autoimmune diseases, skin biopsies were performed in a few patients, revealing small nerve hypertrophy in sensory C fibers [146], indicating that skin pain in long COVID-19 may ascribe to dermal neural hyperexcitability. Small fiber neuropathy is a structural abnormality at the distal termination of small fibers (thin myelinated and unmyelinated fibers of the sensory input and autonomic neu-

rons), which typically presents as progressive and chronic pain. Abbott described three cases of acute persisted skin pain after receiving the Oxford-AstraZeneca ChAdOx1-S vaccine, eventually diagnosed as small fiber neuropathy. Skin biopsy demonstrated that protein gene product 9.5-immunoreactive fibers and single intraepidermal nerve fiber cross the basement membrane of the epidermis [147]. Taken together, we propose nociceptor hyperexcitability and small fiber neuropathy play a crucial role in skeletal muscle pain in long COVID. Local anesthetics (LA) with injections of 0.5% procaine 3 times over 3 months to action site of the autonomic nervous system (ANS) progressively improved a 54-year-old man with post COVID-19 symptoms lasting 14 weeks including muscle pain. These studies strongly supported that the autonomic nervous system (ANS) dysfunction was a contributor to myalgia in long COVID [148].

Other conditions

In addition to the aforementioned factors, other conditions are also associated with skeletal muscle pain in long COVID. The dysregulation of the renin-angiotensin system (RAS) after COVID-19 infection contributes to the occurrence of sustained skeletal muscle pain. When SARS-CoV-2 makes contact with host cells, the expression of ACE2 on membrane of susceptible cells downregulates, leading to deactivation of the alternative ACE2-Ang-(1-7)-Mas pathway which is against fibrosis and atrophy of skeletal muscles. Conversely, overactivation of the classical ACE-Ang II-AT1R pathway which can lead to oxidative stress, neuroinflammation, vasodilation, and thrombosis [149, 150]. Detailed history inquiry and clinical examination are necessary, as skeletal muscle pain in long COVID is also associated with pre-existing skeletal muscle pain history, inappropriate physical exercise [151], harmful effects of hospitalization such as the use of myotoxic drugs, immobility, ventilation was also a risk factor for persisting fatigue and myalgia [152]. Age < 30 years was also found to be an independent risk factor for myalgia post mild and moderate SARS-CoV-2 infection in Jordan [153]. Interestingly, a population-based prospective cohort study in Spain reported that there is a higher incidence of post-COVID-19 myalgia in B group among ABO Blood Groups [154]. Besides, patients infected with Omicron variant were susceptible to myalgia in the long COVID, compared with those infected with the Alpha variant, Delta variant and wild-type strain [155]. Luckily, the risk of muscle pain in patients who had a filled nirmatrelvir or molnupiravir prescription within 5 days of SARS-CoV-2 positive test result decreased at 180 days when compared with control group [156, 157]. Interestingly, there is a significant change in the composition of gut microbiota 1 year post COVID-19 infection [158].

Evaluation

The long COVID has multifaceted influences on the body. To distinguish the etiology of myalgia in long COVID and provide guideline for treatment, multisystem and interdisciplinary evaluations to cover all aspects is necessary. Taken together, we advocate that a comprehensive range of ancillary examination methods, as shown in **Figure 3**.

Pain scales such as the Visual Analog Scale (VAS), Numeric Rating Scale (NRS) [51] assess the nature and intensity of skeletal muscle pain and its impact on daily life. Long COVID contains complex multi-organ disorder, therefore the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS) [159, 160] and the Post-COVID-19 Functional Status scale (PCFS) [161] are recommended to be applied to measure functional outcomes in patients with SARS-CoV-2 infection. Besides, health-related quality of life (HRQoL) can also be measured by the EQ-5D-5L questionnaire before and during the infection [162].

Common hematological indicators of myalgia in long COVID are listed in **Table 1**. They reflect inflammatory state and muscle condition. Blood routine mainly include WBC, lymphocytes and neutrophil count. WBC count > 11×10^9/L was a risk factor associated with persistent myalgia after COVID-19 infection [152].

Inflammation markers have C-reactive protein (CRP), ESR, PCT and serum ferritin. A prospective, longitudinal study revealed that there was no statistical significance differences in blood CRP and D-dimer of hospitalized COVID-19 patients followed-up for 12 months. However, these indicators were higher in long-term symptomatic patients than non-long-term symptomatic patients [163]. CRP was positively corre-



Figure 3. Auxiliary examinations for skeletal muscle pain in long COVID. Muscle biopsy is the gold standard for identifying the cause of skeletal muscle pain. Pain scales are applied to evaluate the nature and intensity of pain while hematological examinations reflect the degree of inflammation and muscle condition. Nerve conduction tests and electromyography help to confirm muscle disease while non-invasive MRI and ultrasound examinations observe histological changes in the affected muscle. Besides, genetic testing help to identify individuals susceptible to myopathy. CPET evaluate oxygen supply condition in the body. Grip strength test is a tool for screening sarcopenia. Created with BioRender.com.

lated with long COVID-19 myalgia at one year after discharge [164]. Besides, common cytokines are IL-1β, IL-6, TNF-α, and INF-γ. It is necessary to check muscle metabolism when patients complain of myalgia. LDH, CK, CK-MB, hs-Troponin-T are widely applied. To diagnose or exclude coexisting rheumatic immune diseases, rheumatoid factor, antinuclear antibody, anticyclic citrullinated peptide, anticardiolipin, and creatine phosphokinase tests are advised [165]. In addition, blood gas analysis reflect the oxygen supply of the body [166]. Certainly, it is recommended that blood oxygen levels can be monitored using a pulse oximeter. At the third month follow-up visit, oxygen saturations at rest and after 6-min walk test of patients with prior intensive care hospitalization were lower than those without [167]. INR, fibrinogen, D-dimer [168-170], aPTT, PT, and TT represent coagulation function. A cross-sectional study following mild COVID-19 cases for 3 months found that patients with persistent myalgia were always along with higher fibrinogen levels [76]. Moreover, plasma proteome profile of patients with fibromyalgia exhibited increased fibrinogen [171]. It is well-known that fibrin engage in inflammation, tissue injury, remodeling, and repair by multiple cellular receptors and mechanisms [172]. Hence, fibrinogen may be a sensitive biological marker of myalgia in long COVID.

Nutritional status is provided by hemoglobin and albumin. Although SARS-CoV-2 can precipitate multisystem disorder and other organ systems can contribute to secondary persistent myalgia, hematological indicators such as ALP, ALT, AST, Creatinine are beneficial to exclude potential involvement of other organ systems [168]. Elevated plasma taurine concentrations were reported in the 3-month COVID-19 follow-up patients with respect to controls. Taurine is not a specific marker but indicative of possible skeletal muscles damage [173]. Last but not least, serum electrolyte mainly potassium and sodium play an important role in skeletal muscle electrophysiology.

Electromyography (EMG) and nerve conduction tests are beneficial to confirm muscle disease and exclude alternative diagnoses such as motor neuron disease [174]. Muscle biopsy is considered as the gold standard for diagnosing muscle diseases, but data on skeletal muscle biopsies in patients with COVID-19 are scarce [175-177]. Sepsis and coagulation dysfunction such as prolonged bleeding and recovery time result in a low muscle biopsy rate. In contrast, non-invasive imaging examinations are more popular. They can support diagnosis and describe histological changes in the affected tissues, with MRI being the preferred method [178-181] and ultrasound being the second one. Mehan described a cohort study of 9 post-COVID-19 patients who underwent spinal MRI, among whom 7 had back pain or bilateral leg pain, and MRI showed paraspinal muscle inflammation in 7 cases, predominantly charac-

terized by intramuscular edema or enhancement, offering a radiological evidence for myositis as a potential mechanism for long COVID-associated myalgia [182]. A small-scale prospective study has indicated attenuation of most plasma skeletal muscle injury indicators such as cardiac troponin Ic and CRP, despite the persistence of extracellular volume (ECV) abnormalities at 3 months after acute COVID-19. In this study, the researchers measured extracellular volume (ECV) in the shoulder skeletal muscle using cardiac magnetic resonance (CMR) in 19 patients without any prior history of cardiac disease but with a peak troponin-Ic > 50 ng/ml at the time of the first COVID-wave. 74% of patients had extracellular volume (ECV) abnormalities in the shoulder skeletal muscle at the first CMR examination (median of 3 months), with most plasma indicators having essentially returned to normal levels. At the second CMR (median of 11 months), ECV in the skeletal muscle had significantly decreased or returned to normal ranges in 13 patients. This study also provides insights into the course of skeletal muscle edema and method of examination after COVID-19 infection [183].

Besides, genetic testing can help to identify individuals susceptible to myopathy. Antioxidant Genetic Profile studies suggested that individuals carrying GSTP1ABIleIle/GSTO1AlaAla/GPX1LeuLeu/GPX3CC genotype were more susceptible with long-COVID myalgia when compared with GSTP1ABValVal/GSTO1AspAsp/GPX1ProPro/GPX3TT genotype, indicating the involvement of genetic susceptibility in long-COVID myalgia [184].

Cardiopulmonary exercise testing (CPET) is a mature test which can be applied to reflect the oxygen supply of patients with persistent skeletal muscle pain after COVID-19. TLC% pred was negatively correlated with long COVID-19 myalgia at one year after discharge [164]. Besides, a portable spirometer (Conter® SP10) is recommended to evaluate respiratory function. Moreover, Grip strength test is an available tool for screening of sarcopenia.

Treatments

Treatment of people with myalgia post acute COVID-19 infection requires a multi-disciplinary approach. Since it is an emerging disease, the knowledge regarding treatment is still evolving. So far, there is no specific pharmacological or surgical treatment for myalgia in long COVID. However, we found that rehabilitation interventions for myalgia in long COVID contain but are not limited to management of pain, strength training [185]. Drug, nutraceutical therapy, gut microbiome-targeted therapy, interventional therapy are beneficial for pain relief in specific circumstance.

Management of pain

Drug: The most common analgesics drugs taken by post-acute COVID-19 outpatient service with persistent myalgia in Italy were acetaminophen (31%), ibuprofen (31%) and other non-steroidal anti-inflammatory drug (NSAID) (29.5%). Analgesic therapy relieved pain in 84% subjects [186]. Besides, immunomodulators such as glucocorticoids play an important role in anti-inflammation [181, 187].

Gabapentinoids (pregabalin) are recommended to be the first-line drug for treatment of fibromyalgia [188]. So far, pregabalin has been proved to relieve pain symptoms [189] and reduce anxiety [190], and chronic cough [191] in patients during and after COVID-19. Gabapentin, another drug which has a similar pharmacokinetic profile but more slowly and variably absorbed than pregabalin, has been reported to effectivly reduce the pain symptom of a 40-year-old woman diagnosed with COVID-19 with acute symptoms while acetaminophen, NSAIDs, and opioids can not alleviate this patient's pain [192]. Therefore, pregabalin and Gabapentin may be promising drugs to treat myalgia in long COVID.

Nutraceutical therapy: Nutraceutical therapy includes polydatin, zinc, melatonin, vitamin D3 [187] and creatine. Polydatin is demonstrated to decrease the production of IL-17 and oxygen free radicals based on peripheral blood mononuclear cells study. This drug is approved by Food and Drug Administration (FDA) from May 2020 to treat COVID-19. Zinc supplementation inhibits gene expression of IL-1β and TNF-α to downregulate inflammatory cytokines [8, 193].

The cytokine storm in long COVID can partly ascribe to the conversion of macrophages from anti-inflammatory M2 to proinflammatory M1, which can be reversed by Melatonin [194]. Besides, melatonin can neutralize cytokines

such as TNF-α, IL-1β, IL-6, IL-8 and IL-10 [195]. Therefore, Melatonin plays a role in antioxidation, anti-inflammation, and immuno-modulation.

Vitamin D as an immunomodulator is able to enhance the development of Th2 cells and suppress Th17 [196, 197]. Since vitamin D reduces renin generation and activates the pro-renin receptor, it has a negative regulatory effect on the RAS [150].

The creatine levels in vastus medialis muscle can be assessed by proton magnetic resonance spectroscopy (MRS), a gold standard noninvasive technique. The creatine concentration of long COVID patients was significantly lower compared with general population. Besides, long COVID patients whose muscle creatine levels were lower were susceptible with more severe myalgia. Exogenous administration of creatine is a possible strategy to correct the deficit and help relieve myalgia in this specific clinical population [198].

Gut microbiome-targeted therapy: Gut microbiome-targeted therapy for the myalgia of PACS exhibit huge potential. The features of gut microbiomes in patients with PACS were decreased microbial diversity and richness, reduced abundance of short-chain fatty-acid producing bacteria after SARS-CoV-2 clearance [164, 199] and increased of pathogenic bacteria such as Klebsiella genus. A micro-encapsulated lyophilised powder, called SIM01, contains 20 billion colonyforming units of three bacterial strains and three prebiotic compounds. The bacterial strains are B adolescentis, Bifidobacterium bifidum and Bifidobacterium longum and the prebiotic compounds are galactooligosaccharides, xylo-oligosaccharides, and resistant dextrin [200]. In a randomised, doubleblind, placebo-controlled trial, more PACS patients in the SIM01 group achieved relieved muscle pain after 6 months of treatment compared with placebo vitamin C group. Increased bacterial diversity and short-chain acid-producing bacteria A and decreased pathogenic bacteria associated with PACS such as Klebsiella genus in the gut microbiota of SIM01 group provide plausible mechanisms to explain the clinical benefits observed for SIM01 in relieving myalgia in long COVID [201].

Interventional therapy: Interestingly, myalgia in long COVID may be a new-onset myofascial pain. Trigger point injections and dry needling achieved effective outcome in relieving short- and long-term pain. However, we need to expand study population to further verify the conclusion [202].

Rehabilitation

The rehabilitation of myalgia in long COVID should be conducted under the guidance of the framework of the International Classification of Functioning, Disability, and Health. It is no doubt that rehabilitation start as early as possible to reduce the harmful effects of the disease such as sarcopenia, thrombosis. Inadequate physical activity was associated with a higher prevalence of myalgia in COVID-19 Survivors with Post-Acute Symptoms [203]. What's more, the type, intensity, frequency, and duration of exercise are supposed to be personalized, incremental and adjustable according to patients' specific goals, demands and priorities [88].

Currently, whole-body cryostimulation (WBC) is being applied for relieving symptoms in fibromyalgia, muscle soreness after strenuous physical exercise [204], post-Covid syndrome [205]. This new physical therapy can train the autonomic nervous system [206] and decrease the production of pro-inflammatory and oxidative substances [207]. Unfortunately, evidence of the clinical benefits of WBC remains preliminary stage because of limited sample sizes and methodological issues. However, we believe that it is a matter of time for the medical use of WBC to be popular in the field of rehabilitation.

Besides, studies revealed that patients suffering from myalgia due to long COVID can benefit from eccentric training (ECC). This is a novel alternative to conventional concentric (CONC) exercise. ECC not only reduces cardiopulmonary stress, inflammatory and oxidative stress (OS), but also improves muscle mass. Consequently, ECC improves cardiopulmonary capacity and mitigates dyspnoea and fatigue. However, ECC can induce muscle injury at the onset of exercise and aged patients are prone to muscle damage. Luckily, muscle damages attenuate when ECC exercises persist [208]. Therefore, it is necessary to monitor the side effect of ECC in order to achieve maximum benefit.

Conclusion

The persistent skeletal muscle pain in long COVID is due to abnormal activation of inflammatory response, myopathy, and neurological damage. In addition, dysregulation of the renin-angiotensin system, history of musculoskeletal pain, myotoxic drugs, immobility, age, blood group, virus strain, anti-virus drugs and gut microbiome contribute to the development of myalgia in Long COVID. We believe that in the future, a comprehensive approach that integrates pain scales, hematological tests, nerve conduction tests, electromyography, muscle biopsy, imaging tests such as MRI and musculoskeletal ultrasound, genetic testing, cardiopulmonary exercise testing, grip strength testing, and other examinations will provide a more detailed comprehension of the pathological and physiological mechanisms of post-COVID-19 persistent musculoskeletal pain. So far, the rate of muscle biopsy in patients with persistent musculoskeletal pain post-COVID-19 is low. Therefore, we call on patients with unrelieved skeletal muscle pain post-COVID-19 to complete this examination as much as possible. Rehabilitation interventions for myalgia in long COVID are limited. So far, interventions are drug, nutraceutical therapy, gut microbiome-targeted therapy, interventional therapy and strength training. The relief of skeletal muscle pain will accelerate rehabilitation process, improve activities of daily living, and enhance the quality of life, promoting individuals return to society with profound significance.

Acknowledgements

This study was supported by grants from the Program for Shanghai Clinical Skills and Innovation Talents (SHDC2020CR1030B), the Program of Shanghai Science and Technology Committee (Grant Nos. 22Y11912100, 20S31905600) and Geriatric Rehabilitation-Nursing Innovation Center Project of Shanghai Sanda University (No. 2023-14). **Figures 1-3** were created with BioRender.com.

Disclosure of conflict of interest

None.

Address correspondence to: Yun Miao, Department of Rehabilitation, Shanghai General Hospital, Shanghai Jiaotong University, No. 100, Haining Road, Shanghai 200080, China. E-mail: miaoyunedu@sina.com

References

[1] Varatharaj A, Thomas N, Ellul MA, Davies NWS, Pollak TA, Tenorio EL, Sultan M, Easton A, Breen G, Zandi M, Coles JP, Manji H, Al-Shahi Salman R, Menon DK, Nicholson TR, Benjamin LA, Carson A, Smith C, Turner MR, Solomon T, Kneen R, Pett SL, Galea I, Thomas RH and Michael BD; CoroNerve Study Group. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry 2020; 7: 875-882.

[2] Stefanou MI, Palaiodimou L, Bakola E, Smyrnis N, Papadopoulou M, Paraskevas GP, Rizos E, Boutati E, Grigoriadis N, Krogias C, Giannopoulos S, Tsiodras S, Gaga M and Tsivgoulis G. Neurological manifestations of long-COVID syndrome: a narrative review. Ther Adv Chronic Dis 2022; 13: 20406223221076890.

[3] Aschman T, Schneider J, Greuel S, Meinhardt J, Streit S, Goebel HH, Büttnerova I, Elezkurtaj S, Scheibe F, Radke J, Meisel C, Drosten C, Radbruch H, Heppner FL, Corman VM and Stenzel W. Association between SARS-CoV-2 infection and immune-mediated myopathy in patients who have died. JAMA Neurol 2021; 78: 948-960.

[4] Duarte-Neto AN, Monteiro RAA, da Silva LFF, Malheiros DMAC, de Oliveira EP, Theodoro-Filho J, Pinho JRR, Gomes-Gouvêa MS, Salles APM, de Oliveira IRS, Mauad T, Saldiva PHN and Dolhnikoff M. Pulmonary and systemic involvement in COVID-19 patients assessed with ultrasound-guided minimally invasive autopsy. Histopathology 2020; 77: 186-197.

[5] Lai CC, Ko WC, Lee PI, Jean SS and Hsueh PR. Extra-respiratory manifestations of COVID-19. Int J Antimicrob Agents 2020; 56: 106024.

[6] Stavem K, Ghanima W, Olsen MK, Gilboe HM and Einvik G. Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax 2021; 76: 405-407.

[7] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY and Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708-1720.

[8] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J and Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.

[9] Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, Huet K, Plzak J, Horoi M, Hans S, Rosaria Barillari M, Cammaroto G, Fakhry N, Martiny D, Ayad T, Jouffe L, Hopkins C and Saussez S; COVID-19 Task Force of YO-IFOS. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med 2020; 288: 335-344.

[10] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X and Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061-1069.

[11] Paliwal VK, Garg RK, Gupta A and Tejan N. Neuromuscular presentations in patients with COVID-19. Neurol Sci 2020; 41: 3039-3056.

[12] Batur EB, Korez MK, Gezer IA, Levendoglu F and Ural O. Musculoskeletal symptoms and relationship with laboratory findings in patients with COVID-19. Int J Clin Pract 2021; 75: e14135.

[13] McFarland AJ, Yousuf MS, Shiers S and Price TJ. Neurobiology of SARS-CoV-2 interactions with the peripheral nervous system: implications for COVID-19 and pain. Pain Rep 2021; 6: e885.

[14] Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, Reeves WC and Lloyd A; Dubbo Infection Outcomes Study Group. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ 2006; 333: 575.

[15] Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL and Kulkarni PA. Postacute COVID-19: an overview and approach to classification. Open Forum Infect Dis 2020; 7: ofaa509.

[16] Chopra N, Chowdhury M, Singh AK, Ma K, Kumar A, Ranjan P, Desai D and Wig N. Clinical predictors of long COVID-19 and phenotypes of mild COVID-19 at a tertiary care centre in India. Drug Discov Ther 2021; 15: 156-161.

[17] Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, Cuadrado ML and Florencio LL. Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): an integrative classification. Int J Environ Res Public Health 2021; 18: 2621.

[18] Dos Santos PK, Sigoli E, Bragança LJG and Cornachione AS. The musculoskeletal involvement after mild to moderate COVID-19 infection. Front Physiol 2022; 13: 813924.

[19] Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D and Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397: 220-232.

[20] Carfì A, Bernabei R and Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020; 324: 603-605.

[21] Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M and Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med 2021; 18: e1003773.

[22] Martone AM, Tosato M, Ciciarello F, Galluzzo V, Zazzara MB, Pais C, Savera G, Calvani R, Marzetti E, Robles MC, Ramirez M and Landi F; Gemelli Against COVID-19 Post-Acute Care Team. Sarcopenia as potential biological substrate of long COVID-19 syndrome: prevalence, clinical features, and risk factors. J Cachexia Sarcopenia Muscle 2022; 13: 1974-1982.

[23] Gransee HM, Mantilla CB and Sieck GC. Respiratory muscle plasticity. Compr Physiol 2012; 2: 1441-1462.

[24] Naddaf E and Milone M. Hereditary myopathies with early respiratory insufficiency in adults. Muscle Nerve 2017; 56: 881-886.

[25] Leth S, Gunst JD, Mathiasen V, Hansen K, Søgaard O, Østergaard L, Jensen-Fangel S, Storgaard M and Agergaard J. Persistent symptoms in patients recovering from COVID-19 in Denmark. Open Forum Infect Dis 2021; 8: ofab042.

[26] Daher A, Balfanz P, Cornelissen C, Müller A, Bergs I, Marx N, Müller-Wieland D, Hartmann B, Dreher M and Müller T. Follow up of patients with severe coronavirus disease 2019 (COVID-19): pulmonary and extrapulmonary disease sequelae. Respir Med 2020; 174: 106197.

[27] Goërtz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, Houben-Wilke S, Burtin C, Posthuma R, Franssen FME, van Loon N, Hajian B, Spies Y, Vijlbrief H, van't Hul AJ, Janssen DJA and Spruit MA. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res 2020; 6: 00542-2020.

[28] Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH and Crooks MG. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? Lung 2021; 199: 113-119.

[29] Jacobs LG, Gourna Paleoudis E, Lesky-Di Bari D, Nyirenda T, Friedman T, Gupta A, Rasouli L, Zetkulic M, Balani B, Ogedegbe C, Bawa H, Berrol L, Qureshi N and Aschner JL. Persistence of symptoms and quality of life at 35 days after

hospitalization for COVID-19 infection. PLoS One 2020; 15: e0243882.
[30] Lu Y, Li X, Geng D, Mei N, Wu PY, Huang CC, Jia T, Zhao Y, Wang D, Xiao A and Yin B. Cerebral micro-structural changes in COVID-19 patients - an MRI-based 3-month follow-up study. EClinicalMedicine 2020; 25: 100484.
[31] Shanbehzadeh S, Tavahomi M, Zanjari N, Ebrahimi-Takamjani I and Amiri-Arimi S. Physical and mental health complications post-COVID-19: scoping review. J Psychosom Res 2021; 147: 110525.
[32] Karaarslan F, Güneri FD and Kardeş S. Long COVID: rheumatologic/musculoskeletal symptoms in hospitalized COVID-19 survivors at 3 and 6 months. Clin Rheumatol 2022; 41: 289-296.
[33] Premraj L, Kannapadi NV, Briggs J, Seal SM, Battaglini D, Fanning J, Suen J, Robba C, Fraser J and Cho SM. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci 2022; 434: 120162.
[34] Taboada M, Moreno E, Cariñena A, Rey T, Pita-Romero R, Leal S, Sanduende Y, Rodríguez A, Nieto C, Vilas E, Ochoa M, Cid M and Seoane-Pillado T. Quality of life, functional status, and persistent symptoms after intensive care of COVID-19 patients. Br J Anaesth 2021; 126: e110-e113.
[35] Ghosn J, Piroth L, Epaulard O, Le Turnier P, Mentré F, Bachelet D and Laouénan C; French COVID cohort study and investigators groups. Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. Clin Microbiol Infect 2021; 27: 1041.e1041-1041.e1044.
[36] Lauwers M, Au M, Yuan S and Wen C. COVID-19 in joint ageing and osteoarthritis: current status and perspectives. Int J Mol Sci 2022; 23: 720.
[37] Fernández-de-Las-Peñas C, Cancela-Cilleruelo I, Moro-López-Menchero P, Rodríguez-Jiménez J, Pellicer-Valero OJ, Martín-Guerrero JD and Arendt-Nielsen L. Exploring the trajectory curve of long-term musculoskeletal post-COVID pain symptoms in hospitalized COVID-19 survivors: a multicenter study. Pain 2023; 164: 413-420.
[38] Zhang X, Wang F, Shen Y, Zhang X, Cen Y, Wang B, Zhao S, Zhou Y, Hu B, Wang M, Liu Y, Miao H, Jones P, Ma X, He Y, Cao G, Cheng L and Li L. Symptoms and health outcomes among survivors of COVID-19 infection 1 year after discharge from hospitals in Wuhan, China. JAMA Netw Open 2021; 4: e2127403.
[39] Shivani F, Kumari N, Bai P, Rakesh F, Haseeb M, Kumar S, Jamil A, Zaidi M, Shaukat F and Rizwan A. Long-term symptoms of COVID-19: one-year follow-up study. Cureus 2022; 14: e25937.
[40] Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M, Obeidat M, Obeidat Y, Gerberi D, Taha RM, Kashour Z, Kashour T, Berbari EF, Alkattan K and Tleyjeh IM. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect 2022; 28: 657-666.
[41] Rass V, Beer R, Schiefecker AJ, Lindner A, Kofler M, Ianosi BA, Mahlknecht P, Heim B, Peball M, Carbone F, Limmert V, Kindl P, Putnina L, Fava E, Sahanic S, Sonnweber T, Löscher WN, Wanschitz JV, Zamarian L, Djamshidian A, Tancevski I, Weiss G, Bellmann-Weiler R, Kiechl S, Seppi K, Loeffler-Ragg J, Pfausler B and Helbok R. Neurological outcomes 1 year after COVID-19 diagnosis: a prospective longitudinal cohort study. Eur J Neurol 2022; 29: 1685-1696.
[42] Fernández-de-Las-Peñas C, Navarro-Santana M, Plaza-Manzano G, Palacios-Ceña D and Arendt-Nielsen L. Time course prevalence of post-COVID pain symptoms of musculoskeletal origin in patients who had survived severe acute respiratory syndrome coronavirus 2 infection: a systematic review and meta-analysis. Pain 2022; 163: 1220-1231.
[43] Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, DiBiase RM, Jia DT, Balabanov R, Ho SU, Batra A, Liotta EM and Koralnik IJ. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers". Ann Clin Transl Neurol 2021; 8: 1073-1085.
[44] Fernández-de-Las-Peñas C, Rodríguez-Jiménez J, Fuensalida-Novo S, Palacios-Ceña M, Gómez-Mayordomo V, Florencio LL, Hernández-Barrera V and Arendt-Nielsen L. Myalgia as a symptom at hospital admission by severe acute respiratory syndrome coronavirus 2 infection is associated with persistent musculoskeletal pain as long-term post-COVID sequelae: a case-control study. Pain 2021; 162: 2832-2840.
[45] Fernández-de-Las-Peñas C, de-la-Llave-Rincón AI, Ortega-Santiago R, Ambite-Quesada S, Gómez-Mayordomo V, Cuadrado ML, Arias-Navalón JA, Hernández-Barrera V, Martín-Guerrero JD, Pellicer-Valero OJ and Arendt-Nielsen L. Prevalence and risk factors of musculoskeletal pain symptoms as long-term post-COVID sequelae in hospitalized COVID-19 survivors: a multicenter study. Pain 2022; 163: e989-e996.
[46] da Silva NS, de Araújo NK, Dos Santos KA, de Souza KSC, de Araújo JNG, Cruz MS, Parra EJ, Silbiger VN and Luchessi AD. Post-Covid condition and clinic characteristics associated with SARS-CoV-2 infection: a 2-year follow-up to Brazilian cases. Sci Rep 2023; 13: 13973.

[47] Pelà G, Goldoni M, Solinas E, Cavalli C, Tagliaferri S, Ranzieri S, Frizzelli A, Marchi L, Mori PA, Majori M, Aiello M, Corradi M and Chetta A. Sex-related differences in long-COVID-19 syndrome. J Womens Health (Larchmt) 2022; 31: 620-630.

[48] Bakılan F, Gökmen İG, Ortanca B, Uçan A, Eker Güvenç Ş, Şahin Mutlu F, Gökmen HM and Ekim A. Musculoskeletal symptoms and related factors in postacute COVID-19 patients. Int J Clin Pract 2021; 75: e14734.

[49] Shiers S, Ray PR, Wangzhou A, Sankaranarayanan I, Tatsui CE, Rhines LD, Li Y, Uhelski ML, Dougherty PM and Price TJ. ACE2 and SCARF expression in human dorsal root ganglion nociceptors: implications for SARS-CoV-2 virus neurological effects. Pain 2020; 161: 2494-2501.

[50] Román-Montes CM, Flores-Soto Y, Guaracha-Basañez GA, Tamez-Torres KM, Sifuentes-Osornio J, González-Lara MF and de León AP. Post-COVID-19 syndrome and quality of life impairment in severe COVID-19 Mexican patients. Front Public Health 2023; 11: 1155951.

[51] Orrù G, Bertelloni D, Diolaiuti F, Mucci F, Di Giuseppe M, Biella M, Gemignani A, Ciacchini R and Conversano C. Long-COVID syndrome? A study on the persistence of neurological, psychological and physiological symptoms. Healthcare (Basel) 2021; 9: 575.

[52] Soh HS and Cho B. Long COVID-19 and health-related quality of life of mild cases in Korea: 3-months follow-up of a single community treatment center. J Korean Med Sci 2022; 37: e326.

[53] Erden E, Turk AC, Erden E and Dag Z. Musculoskeletal system symptoms in patients with COVID-19 and the impact of these symptoms on quality of life. J Back Musculoskelet Rehabil 2023; 36: 1061-1074.

[54] Sun W, Gao H, Luo Y, Zheng H, Liao X, Xiong D and Xiao L. Management of immunity alteration-induced chronic pain during the coronavirus disease-2019 (COVID-19) pandemic. Front Microbiol 2020; 11: 572318.

[55] Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A and Li F. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A 2020; 117: 11727-11734.

[56] Ferrandi PJ, Alway SE and Mohamed JS. The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies. J Appl Physiol (1985) 2020; 129: 864-867.

[57] Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S and Adeli K. Pathophysiology of COVID-19: mechanisms underlying disease severity and progression. Physiology (Bethesda) 2020; 35: 288-301.

[58] Gonzalez A, Orozco-Aguilar J, Achiardi O, Simon F and Cabello-Verrugio C. SARS-CoV-2/Renin-angiotensin system: deciphering the clues for a couple with potentially harmful effects on skeletal muscle. Int J Mol Sci 2020; 21: 7904.

[59] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C and Pöhlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271-280, e278.

[60] Perez-Valera M, Martinez-Canton M, Gallego-Selles A, Galván-Alvarez V, Gelabert-Rebato M, Morales-Alamo D, Santana A, Martin-Rodriguez S, Ponce-Gonzalez JG, Larsen S, Losa-Reyna J, Perez-Suarez I, Dorado C, Curtelin D, Gonzalez-Henriquez JJ, Boushel R, Hallen J, de Pablos Velasco P, Freixinet-Gilart J, Holmberg HC, Helge JW, Martin-Rincon M and Calbet JAL. Angiotensin-converting enzyme 2 (SARS-CoV-2 receptor) expression in human skeletal muscle. Scand J Med Sci Sports 2021; 31: 2249-2258.

[61] Hikmet F, Méar L, Edvinsson Å, Micke P, Uhlén M and Lindskog C. The protein expression profile of ACE2 in human tissues. Mol Syst Biol 2020; 16: e9610.

[62] Shi Z, de Vries HJ, Vlaar APJ, van der Hoeven J, Boon RA, Heunks LMA and Ottenheijm CAC; Dutch COVID-19 Diaphragm Investigators. Diaphragm pathology in critically ill patients with COVID-19 and postmortem findings from 3 medical centers. JAMA Intern Med 2021; 181: 122-124.

[63] Suh J, Mukerji SS, Collens SI, Padera RF Jr, Pinkus GS, Amato AA and Solomon IH. Skeletal muscle and peripheral nerve histopathology in COVID-19. Neurology 2021; 97: e849-e858.

[64] Manzano GS, Woods JK and Amato AA. Covid-19-associated myopathy caused by type I interferonopathy. N Engl J Med 2020; 383: 2389-2390.

[65] Barragán-Iglesias P, Franco-Enzástiga Ú, Jeevakumar V, Shiers S, Wangzhou A, Granados-Soto V, Campbell ZT, Dussor G and Price TJ. Type I interferons act directly on nociceptors to produce pain sensitization: implications for viral infection-induced pain. J Neurosci 2020; 40: 3517-3532.

[66] Doykov I, Hällqvist J, Gilmour KC, Grandjean L, Mills K and Heywood WE. 'The long tail of Covid-19' - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Res 2020; 9: 1349.

[67] Colosio M, Brocca L, Gatti MF, Neri M, Crea E, Cadile F, Canepari M, Pellegrino MA, Polla B, Porcelli S and Bottinelli R. Structural and func-

tional impairments of skeletal muscle in patients with postacute sequelae of SARS-CoV-2 infection. J Appl Physiol (1985) 2023; 135: 902-917.
[68] Finsterer J and Scorza FA. Exercise intolerance in post-COVID syndrome cannot only be due to skeletal muscle impairment. J Appl Physiol (1985) 2023; 135: 1384-1385.
[69] Polese J, Ramos AD, Moulaz IR, Sant'Ana L, Lacerda BSP, Soares CES, Lança KEM, Thompson BP, Júnior GPB, Polese Pinto II and Mill JG. Pulmonary function and exercise capacity six months after hospital discharge of patients with severe COVID-19. Braz J Infect Dis 2023; 27: 102789.
[70] Singh I, Joseph P, Heerdt PM, Cullinan M, Lutchmansingh DD, Gulati M, Possick JD, Systrom DM and Waxman AB. Persistent exertional intolerance after COVID-19: insights from invasive cardiopulmonary exercise testing. Chest 2022; 161: 54-63.
[71] Baratto C, Caravita S, Faini A, Perego GB, Senni M, Badano LP and Parati G. Impact of COVID-19 on exercise pathophysiology: a combined cardiopulmonary and echocardiographic exercise study. J Appl Physiol (1985) 2021; 130: 1470-1478.
[72] Boengler K, Kosiol M, Mayr M, Schulz R and Rohrbach S. Mitochondria and ageing: role in heart, skeletal muscle and adipose tissue. J Cachexia Sarcopenia Muscle 2017; 8: 349-369.
[73] Alway SE, Mohamed JS and Myers MJ. Mitochondria initiate and regulate sarcopenia. Exerc Sport Sci Rev 2017; 45: 58-69.
[74] López-Otín C, Blasco MA, Partridge L, Serrano M and Kroemer G. The hallmarks of aging. Cell 2013; 153: 1194-1217.
[75] Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, Juno JA, Burrell LM, Kent SJ, Dore GJ, Kelleher AD and Matthews GV. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol 2022; 23: 210-216.
[76] Maamar M, Artime A, Pariente E, Fierro P, Ruiz Y, Gutiérrez S, Tobalina M, Díaz-Salazar S, Ramos C, Olmos JM and Hernández JL. Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study. Curr Med Res Opin 2022; 38: 901-909.
[77] Cicco S, Cicco G, Racanelli V and Vacca A. Neutrophil extracellular traps (NETs) and damage-associated molecular patterns (DAMPs): two potential targets for COVID-19 treatment. Mediators Inflamm 2020; 2020: 7527953.
[78] Coperchini F, Chiovato L, Croce L, Magri F and Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev 2020; 53: 25-32.
[79] Behrens EM and Koretzky GA. Review: cytokine storm syndrome: looking toward the precision medicine era. Arthritis Rheumatol 2017; 69: 1135-1143.
[80] Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, O'Mahony L, Gao Y, Nadeau K and Akdis CA. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020; 75: 1564-1581.
[81] Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I and Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 2020; 39: 2085-2094.
[82] Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X and Zhang S. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol 2020; 214: 108393.
[83] Authier FJ, Chazaud B, Plonquet A, Eliezer-Vanerot MC, Poron F, Belec L, Barlovatz-Meimon G and Gherardi RK. Differential expression of the IL-1 system components during in vitro myogenesis: implication of IL-1beta in induction of myogenic cell apoptosis. Cell Death Differ 1999; 6: 1012-1021.
[84] Forcina L, Miano C, Scicchitano BM, Rizzuto E, Berardinelli MG, De Benedetti F, Pelosi L and Musarò A. Increased circulating levels of interleukin-6 affect the redox balance in skeletal muscle. Oxid Med Cell Longev 2019; 2019: 3018584.
[85] Tang H, Pang S, Wang M, Xiao X, Rong Y, Wang H and Zang YQ. TLR4 activation is required for IL-17-induced multiple tissue inflammation and wasting in mice. J Immunol 2010; 185: 2563-2569.
[86] Reid MB and Li YP. Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir Res 2001; 2: 269-272.
[87] VanderVeen BN, Fix DK, Montalvo RN, Counts BR, Smuder AJ, Murphy EA, Koh HJ and Carson JA. The regulation of skeletal muscle fatigability and mitochondrial function by chronically elevated interleukin-6. Exp Physiol 2019; 104: 385-397.
[88] Swarnakar R, Jenifa S and Wadhwa S. Musculoskeletal complications in long COVID-19: a systematic review. World J Virol 2022; 11: 485-495.
[89] Moran EM and Mastaglia FL. Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol 2014; 178: 405-415.

[90] Hund E. Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J Neurol 2001; 248: 929-934.
[91] Batiha GE, Al-Kuraishy HM, Al-Gareeb AI and Welson NN. Pathophysiology of post-COVID syndromes: a new perspective. Virol J 2022; 19: 158.
[92] Akin C, Valent P and Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol 2010; 126: 1099-1104, e1094.
[93] Akin C. Mast cell activation syndromes. J Allergy Clin Immunol 2017; 140: 349-355.
[94] Komi DEA, Khomtchouk K and Santa Maria PL. A review of the contribution of mast cells in wound healing: involved molecular and cellular mechanisms. Clin Rev Allergy Immunol 2020; 58: 298-312.
[95] Dina OA, Green PG and Levine JD. Role of interleukin-6 in chronic muscle hyperalgesic priming. Neuroscience 2008; 152: 521-525.
[96] Manjavachi MN, Motta EM, Marotta DM, Leite DFP and Calixto JB. Mechanisms involved in IL-6-induced muscular mechanical hyperalgesia in mice. Pain 2010; 151: 345-355.
[97] Zhang C, Wu Z, Li JW, Zhao H and Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020; 55: 105954.
[98] Reyes-Long S, Cortés-Altamirano JL, Bandala C, Avendaño-Ortiz K, Bonilla-Jaime H, Bueno-Nava A, Ávila-Luna A, Sánchez-Aparicio P, Clavijo-Cornejo D, Dotor-LLerena AL, Cabrera-Ruiz E and Alfaro-Rodríguez A. Role of the microRNAs in the pathogenic mechanism of painful symptoms in long COVID: systematic review. Int J Mol Sci 2023; 24: 3574.
[99] Silva CC, Bichara CNC, Carneiro FRO, Palacios VRDCM, Berg AVSVD, Quaresma JAS and Magno Falcão LF. Muscle dysfunction in the long coronavirus disease 2019 syndrome: pathogenesis and clinical approach. Rev Med Virol 2022; 32: e2355.
[100] Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M and Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48: 601.
[101] Landi F, Calvani R, Martone AM, Salini S, Zazzara MB, Candeloro M, Coelho-Junior HJ, Tosato M, Picca A and Marzetti E. Normative values of muscle strength across ages in a 'real world' population: results from the longevity check-up 7+ project. J Cachexia Sarcopenia Muscle 2020; 11: 1562-1569.
[102] Gil S, de Oliveira Júnior GN, Sarti FM, Filho WJ, Longobardi I, Turri JAO, Shinjo SK, Ferriolli E, Avelino-Silva TJ, Busse AL, Gualano B and Roschel H. Acute muscle mass loss predicts long-term fatigue, myalgia, and health care costs in COVID-19 survivors. J Am Med Dir Assoc 2023; 24: 10-16.
[103] Agergaard J, Leth S, Pedersen TH, Harbo T, Blicher JU, Karlsson P, Østergaard L, Andersen H and Tankisi H. Myopathic changes in patients with long-term fatigue after COVID-19. Clin Neurophysiol 2021; 132: 1974-1981.
[104] Hannah JR, Ali SS, Nagra D, Adas MA, Buazon AD, Galloway JB and Gordon PA. Skeletal muscles and Covid-19: a systematic review of rhabdomyolysis and myositis in SARS-CoV-2 infection. Clin Exp Rheumatol 2022; 40: 329-338.
[105] Anthony S, Phrathep DD, El-Husari A, Ismaili A, Healey KD and Scott R. Post-COVID-19 polymyositis: a case report. Cureus 2022; 14: e30991.
[106] Amin S, Rahim F, Noor M, Bangash A and Ghani F. Polymyositis: the comet tail after COVID-19. Cureus 2022; 14: e26453.
[107] Saif DS, Ibrahem RA and Eltabl MA. Prevalence of peripheral neuropathy and myopathy in patients post-COVID-19 infection. Int J Rheum Dis 2022; 25: 1246-1253.
[108] Megremis S, Walker TDJ, He X, Ollier WER, Chinoy H, Hampson L, Hampson I and Lamb JA. Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis. Ann Rheum Dis 2020; 79: 1383-1386.
[109] Lokineni S and Mortezavi M. Delayed-onset necrotizing myositis following COVID-19 infection. Eur J Case Rep Intern Med 2021; 8: 002461.
[110] Hejbøl EK, Harbo T, Agergaard J, Madsen LB, Pedersen TH, Østergaard LJ, Andersen H, Schrøder HD and Tankisi H. Myopathy as a cause of fatigue in long-term post-COVID-19 symptoms: evidence of skeletal muscle histopathology. Eur J Neurol 2022; 29: 2832-2841.
[111] Lerma LA, Chaudhary A, Bryan A, Morishima C, Wener MH and Fink SL. Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19). J Transl Autoimmun 2020; 3: 100073.
[112] Sapkota HR and Nune A. Long COVID from rheumatology perspective - a narrative review. Clin Rheumatol 2022; 41: 337-348.
[113] Geng Y, Ma Q, Du YS, Peng N, Yang T, Zhang SY, Wu FF, Lin HL and Su L. Rhabdomyolysis is associated with in-hospital mortality in patients with COVID-19. Shock 2021; 56: 360-367.

[114] He YC and Chen F. Rhabdomyolysis as potential late complication associated with COVID-19. Emerg Infect Dis 2020; 26: 2297-2298.
[115] Zhang Q, Shan KS, Minalyan A, O'Sullivan C and Nace T. A rare presentation of coronavirus disease 2019 (COVID-19) induced viral myositis with subsequent rhabdomyolysis. Cureus 2020; 12: e8074.
[116] Merbouh M, El Aidouni G, Serbource J, Couprie LM, Bernardoni C, Housni B and Monchi M. Isolated severe rhabdomyolisis revealing COVID-19: case report. Oxf Med Case Reports 2022; 2022: omac039.
[117] Suh J and Amato AA. Neuromuscular complications of coronavirus disease-19. Curr Opin Neurol 2021; 34: 669-674.
[118] Islam B, Ahmed M, Islam Z and Begum SM. Severe acute myopathy following SARS-CoV-2 infection: a case report and review of recent literature. Skelet Muscle 2021; 11: 10.
[119] Finsterer J and Scorza F. SARS-CoV-2 associated rhabdomyolysis in 32 patients. Turk J Med Sci 2021; 51: 1598-1601.
[120] Tan A, Stepien KM and Narayana STK. Carnitine palmitoyltransferase II deficiency and post-COVID vaccination rhabdomyolysis. QJM 2021; 114: 596-597.
[121] Wongkittichote P, Watson JR, Leonard JM, Toolan ER, Dickson PI and Grange DK. Fatal COVID-19 infection in a patient with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: a case report. JIMD Rep 2020; 56: 40-45.
[122] Taquet M, Geddes JR, Husain M, Luciano S and Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 2021; 8: 416-427.
[123] Ftiha F, Shalom M and Jradeh H. Neurological symptoms due to Coronavirus disease 2019. Neurol Int 2020; 12: 8639.
[124] Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y and Hu B. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020; 77: 683-690.
[125] Zuberbühler P, Conti ME, León-Cejas L, Maximiliano-González F, Bonardo P, Miquelini A, Halfon J, Martínez J, Gutiérrez MV and Reisin R. Guillain-Barre syndrome associated to COVID-19 infection: a review of published case reports. Rev Neurol 2021; 72: 203-212.
[126] Diamond KB, Weisberg MD, Ng MK, Erez O and Edelstein D. COVID-19 peripheral neuropathy: a report of three cases. Cureus 2021; 13: e18132.
[127] Bureau BL, Obeidat A, Dhariwal MS and Jha P. Peripheral neuropathy as a complication of SARS-Cov-2. Cureus 2020; 12: e11452.
[128] Andalib S, Biller J, Di Napoli M, Moghimi N, McCullough LD, Rubinos CA, O'Hana Nobleza C, Azarpazhooh MR, Catanese L, Elicer I, Jafari M, Liberati F, Camejo C, Torbey M and Divani AA. Peripheral nervous system manifestations associated with COVID-19. Curr Neurol Neurosci Rep 2021; 21: 9.
[129] Wang JJ, Zhang QF, Liu D, Du Q, Xu C, Wu QX, Tang Y and Jin WS. Self-reported neurological symptoms two years after hospital discharge among COVID-19 survivors. J Alzheimers Dis Rep 2023; 7: 1127-1132.
[130] Patel UK, Mehta N, Patel A, Patel N, Ortiz JF, Khurana M, Urhoghide E, Parulekar A, Bhriguvanshi A, Patel N, Mistry AM, Patel R, Arumaithurai K and Shah S. Long-term neurological sequelae among severe COVID-19 patients: a systematic review and meta-analysis. Cureus 2022; 14: e29694.
[131] Solomon IH, Normandin E, Bhattacharyya S, Mukerji SS, Keller K, Ali AS, Adams G, Hornick JL, Padera RF Jr and Sabeti P. Neuropathological features of Covid-19. N Engl J Med 2020; 383: 989-992.
[132] Brann DH, Tsukahara T, Weinreb C, Lipovsek M, Van den Berge K, Gong B, Chance R, Macaulay IC, Chou HJ, Fletcher RB, Das D, Street K, de Bezieux HR, Choi YG, Risso D, Dudoit S, Purdom E, Mill J, Hachem RA, Matsunami H, Logan DW, Goldstein BJ, Grubb MS, Ngai J and Datta SR. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv 2020; 6: eabc5801.
[133] Matschke J, Lütgehetmann M, Hagel C, Sperhake JP, Schröder AS, Edler C, Mushumba H, Fitzek A, Allweiss L, Dandri M, Dottermusch M, Heinemann A, Pfefferle S, Schwabenland M, Sumner Magruder D, Bonn S, Prinz M, Gerloff C, Püschel K, Krasemann S, Aepfelbacher M and Glatzel M. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol 2020; 19: 919-929.
[134] Huang YH, Jiang D and Huang JT. SARS-CoV-2 detected in cerebrospinal fluid by PCR in a case of COVID-19 encephalitis. Brain Behav Immun 2020; 87: 149.
[135] Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, Ueno M, Sakata H, Kondo K, Myose N, Nakao A, Takeda M, Haro H, Inoue O, Suzuki-Inoue K, Kubokawa K, Ogihara S, Sasaki T, Kinouchi H, Kojin H, Ito M, Onishi H, Shimizu T, Sasaki Y, Enomoto N, Ishihara H, Furuya S, Yamamoto T and Shimada S. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis 2020; 94: 55-58.
[136] Paniz-Mondolfi A, Bryce C, Grimes Z, Gordon RE, Reidy J, Lednicky J, Sordillo EM and Fowkes M. Central nervous system involvement by se-

vere acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol 2020; 92: 699-702.
[137] Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, Laue M, Schneider J, Brünink S, Greuel S, Lehmann M, Hassan O, Aschman T, Schumann E, Chua RL, Conrad C, Eils R, Stenzel W, Windgassen M, Rößler L, Goebel HH, Gelderblom HR, Martin H, Nitsche A, Schulz-Schaeffer WJ, Hakroush S, Winkler MS, Tampe B, Scheibe F, Körtvélyessy P, Reinhold D, Siegmund B, Kühl AA, Elezkurtaj S, Horst D, Oesterhelweg L, Tsokos M, Ingold-Heppner B, Stadelmann C, Drosten C, Corman VM, Radbruch H and Heppner FL. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci 2021; 24: 168-175.
[138] Tolebeyan AS, Zhang N, Cooper V and Kuruvilla DE. Headache in patients with severe acute respiratory syndrome coronavirus 2 infection: a narrative review. Headache 2020; 60: 2131-2138.
[139] Kerkman JN, Daffertshofer A, Gollo LL, Breakspear M and Boonstra TW. Network structure of the human musculoskeletal system shapes neural interactions on multiple time scales. Sci Adv 2018; 4: eaat0497.
[140] Mense S. The pathogenesis of muscle pain. Curr Pain Headache Rep 2003; 7: 419-425.
[141] Moy JK, Khoutorsky A, Asiedu MN, Black BJ, Kuhn JL, Barragán-Iglesias P, Megat S, Burton MD, Burgos-Vega CC, Melemedjian OK, Boitano S, Vagner J, Gkogkas CG, Pancrazio JJ, Mogil JS, Dussor G, Sonenberg N and Price TJ. The MNK-eIF4E signaling axis contributes to injury-induced nociceptive plasticity and the development of chronic pain. J Neurosci 2017; 37: 7481-7499.
[142] Mody PH, Dos Santos NL, Barron LR, Price TJ and Burton MD. eIF4E phosphorylation modulates pain and neuroinflammation in the aged. Geroscience 2020; 42: 1663-1674.
[143] Moy JK, Khoutorsky A, Asiedu MN, Dussor G and Price TJ. eIF4E phosphorylation influences Bdnf mRNA translation in mouse dorsal root ganglion neurons. Front Cell Neurosci 2018; 12: 29.
[144] Bocci T, Bertini A, Campiglio L, Botta S, Libelli G, Guidetti M and Priori A. Not myopathic, but autonomic changes in patients with long-COVID syndrome: a case series. Neurol Sci 2023; 44: 1147-1153.
[145] Abrams RMC, Simpson DM, Navis A, Jette N, Zhou L and Shin SC. Small fiber neuropathy associated with SARS-CoV-2 infection. Muscle Nerve 2022; 65: 440-443.
[146] Grieco T, Gomes V, Rossi A, Cantisani C, Greco ME, Rossi G, Sernicola A and Pellacani G. The pathological culprit of neuropathic skin pain in long COVID-19 patients: a case series. J Clin Med 2022; 11: 4474.
[147] Abbott MG, Allawi Z, Hofer M, Ansorge O, Brady S, Fadic R, Torres G, Knight R, Calvo M, Bennett DLH and Themistocleous AC. Acute small fiber neuropathy after Oxford-AstraZeneca ChAdOx1-S vaccination: a report of three cases and review of the literature. J Peripher Nerv Syst 2022; 27: 325-329.
[148] Vinyes D, Muñoz-Sellart M and Caballero TG. Local anesthetics as a therapeutic tool for post COVID-19 patients: a case report. Medicine (Baltimore) 2022; 101: e29358.
[149] Saravi B, Li Z, Lang CN, Schmid B, Lang FK, Grad S, Alini M, Richards RG, Schmal H, Südkamp N and Lang GM. The tissue renin-angiotensin system and its role in the pathogenesis of major human diseases: quo vadis? Cells 2021; 10: 650.
[150] Khazaal S, Harb J, Rima M, Annweiler C, Wu Y, Cao Z, Abi Khattar Z, Legros C, Kovacic H, Fajloun Z and Sabatier JM. The pathophysiology of long COVID throughout the renin-angiotensin system. Molecules 2022; 27: 2903.
[151] Twisk FN and Maes M. A review on cognitive behavorial therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME/CFS. Neuro Endocrinol Lett 2009; 30: 284-299.
[152] Aul DR, Gates DJ, Draper DA, Dunleavy DA, Ruickbie DS, Meredith DH, Walters DN, van Zeller DC, Taylor DV, Bridgett DM, Dunwoody DR, Grubnic DS, Jacob DT and Ean Ong DY. Complications after discharge with COVID-19 infection and risk factors associated with development of post-COVID pulmonary fibrosis. Respir Med 2021; 188: 106602.
[153] Al-Husinat L, Nusir M, Al-Gharaibeh H, Alomari AA, Smadi MM, Battaglini D and Pelosi P. Post-COVID-19 syndrome symptoms after mild and moderate SARS-CoV-2 infection. Front Med (Lausanne) 2022; 9: 1017257.
[154] Domènech-Montoliu S, Puig-Barberà J, Pac-Sa MR, Vidal-Utrillas P, Latorre-Poveda M, Rio-González AD, Ferrando-Rubert S, Ferrer-Abad G, Sánchez-Urbano M, Aparisi-Esteve L, Badenes-Marques G, Cervera-Ferrer B, Clerig-Arnau U, Dols-Bernad C, Fontal-Carcel M, Gomez-Lanas L, Jovani-Sales D, León-Domingo MC, Llopico-Vilanova MD, Moros-Blasco M, Notari-Rodríguez C, Ruíz-Puig R, Valls-López S and Arnedo-Pena A. ABO Blood Groups and the incidence of complications in COVID-19 patients: a population-based prospective cohort study. Int J Environ Res Public Health 2021; 18: 10039.

[155] Kayaaslan B, Eser F, Kalem AK, Kaya G, Kaplan B, Kacar D, Hasanoglu I, Coskun B and Guner R. Post-COVID syndrome: a single-center questionnaire study on 1007 participants recovered from COVID-19. J Med Virol 2021; 93: 6566-6574.
[156] Xie Y, Choi T and Al-Aly Z. Association of treatment with Nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med 2023; 183: 554-564.
[157] Xie Y, Choi T and Al-Aly Z. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ 2023; 381: e074572.
[158] Su Q, Lau RI, Liu Q, Chan FKL and Ng SC. Post-acute COVID-19 syndrome and gut dysbiosis linger beyond 1 year after SARS-CoV-2 clearance. Gut 2023; 72: 1230-1232.
[159] O'Connor RJ, Preston N, Parkin A, Makower S, Ross D, Gee J, Halpin SJ, Horton M and Sivan M. The COVID-19 Yorkshire Rehabilitation Scale (C19-YRS): application and psychometric analysis in a post-COVID-19 syndrome cohort. J Med Virol 2022; 94: 1027-1034.
[160] Yilmaz Gokmen G, Durmaz D, Demir C and Yilmaz FN. Determining post-COVID-19 symptoms and rehabilitation needs in hospitalized and nonhospitalized COVID-19 survivors with tele-assessment methods. Telemed J E Health 2023; 29: 1312-1323.
[161] Klok FA, Boon GJAM, Barco S, Endres M, Geelhoed JJM, Knauss S, Rezek SA, Spruit MA, Vehreschild J and Siegerink B. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. Eur Respir J 2020; 56: 2001494.
[162] Smith P, De Pauw R, Van Cauteren D, Demarest S, Drieskens S, Cornelissen L, Devleesschauwer B, De Ridder K and Charafeddine R. Post COVID-19 condition and health-related quality of life: a longitudinal cohort study in the Belgian adult population. BMC Public Health 2023; 23: 1433.
[163] García-Abellán J, Fernández M, Padilla S, García JA, Agulló V, Lozano V, Ena N, García-Sánchez L, Gutiérrez F and Masiá M. Immunologic phenotype of patients with long-COVID syndrome of 1-year duration. Front Immunol 2022; 13: 920627.
[164] Zhang D, Zhou Y, Ma Y, Chen P, Tang J, Yang B, Li H, Liang M, Xue Y, Liu Y, Zhang J and Wang X. Gut microbiota dysbiosis correlates with long COVID-19 at one-year after discharge. J Korean Med Sci 2023; 38: e120.
[165] Waterbury S. Post-COVID conditions-What practitioners need to know. Nurse Pract 2021; 46: 44-49.
[166] Crook H, Raza S, Nowell J, Young M and Edison P. Long covid-mechanisms, risk factors, and management. BMJ 2021; 374: n1648.
[167] Sarıoğlu N, Aksu GD, Çoban H, Bülbül E, Demirpolat G, Arslan AT and Erel F. Clinical and radiological outcomes of longCOVID: is the post-COVID fibrosis common? Tuberk Toraks 2023; 71: 48-57.
[168] Gameil MA, Marzouk RE, Elsebaie AH and Rozaik SE. Long-term clinical and biochemical residue after COVID-19 recovery. Egypt Liver J 2021; 11: 74.
[169] Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A and Villapol S. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021; 11: 16144.
[170] Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, Heightman M, Hillman TE, Jacob J, Jarvis HC, Lipman MCI, Naidu SB, Nair A, Porter JC, Tomlinson GS and Hurst JR; ARC Study Group. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 2021; 76: 396-398.
[171] Wåhlén K, Ernberg M, Kosek E, Mannerkorpi K, Gerdle B and Ghafouri B. Significant correlation between plasma proteome profile and pain intensity, sensitivity, and psychological distress in women with fibromyalgia. Sci Rep 2020; 10: 12508.
[172] Luyendyk JP, Schoenecker JG and Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. Blood 2019; 133: 511-520.
[173] Nanobashvili J, Neumayer C, Fügl A, Punz A, Blumer R, Prager M, Mittlböck M, Gruber H, Polterauer P, Roth E, Malinski T and Huk I. Ischemia/reperfusion injury of skeletal muscle: plasma taurine as a measure of tissue damage. Surgery 2003; 133: 91-100.
[174] Paganoni S and Amato A. Electrodiagnostic evaluation of myopathies. Phys Med Rehabil Clin N Am 2013; 24: 193-207.
[175] Versace V, Sebastianelli L, Ferrazzoli D, Saltuari L, Kofler M, Löscher W and Uncini A. Case report: myopathy in critically ill COVID-19 patients: a consequence of hyperinflammation? Front Neurol 2021; 12: 625144.
[176] Whittaker A, Anson M and Harky A. Neurological Manifestations of COVID-19: a systematic review and current update. Acta Neurol Scand 2020; 142: 14-22.
[177] Kissel JT. Muscle biopsy in patients with myalgia: still a painful decision. Neurology 2007; 68: 170-171.
[178] Ramani SL, Samet J, Franz CK, Hsieh C, Nguyen CV, Horbinski C and Deshmukh S. Musculoskeletal involvement of COVID-19: review of imaging. Skeletal Radiol 2021; 50: 1763-1773.
[179] Revzin MV, Raza S, Srivastava NC, Warshawsky R, D'Agostino C, Malhotra A, Bader AS, Patel RD, Chen K, Kyriakakos C and Pellerito JS. Mul-

tisystem imaging manifestations of COVID-19, part 2: from cardiac complications to pediatric manifestations. Radiographics 2020; 40: 1866-1892.
[180] Smitaman E, Flores DV, Mejía Gómez C and Pathria MN. MR imaging of atraumatic muscle disorders. Radiographics 2018; 38: 500-522.
[181] Shetty ND, Dhande RP, Nagendra V, Unadkat BS and Shelar SS. Post-COVID-19 myositis based on magnetic resonance imaging: a case report. Cureus 2022; 14: e30293.
[182] Mehan WA, Yoon BC, Lang M, Li MD, Rincon S and Buch K. Paraspinal myositis in patients with COVID-19 infection. AJNR Am J Neuroradiol 2020; 41: 1949-1952.
[183] Filippetti L, Pace N, Louis JS, Mandry D, Goehringer F, Rocher MS, Jay N, Selton-Suty C, Hossu G, Huttin O and Marie PY. Long-lasting myocardial and skeletal muscle damage evidenced by serial CMR during the first year in COVID-19 patients from the first wave. Front Cardiovasc Med 2022; 9: 831580.
[184] Ercegovac M, Asanin M, Savic-Radojevic A, Ranin J, Matic M, Djukic T, Coric V, Jerotic D, Todorovic N, Milosevic I, Stevanovic G, Simic T, Bukumiric Z and Pljesa-Ercegovac M. Antioxidant genetic profile modifies probability of developing neurological sequelae in Long-COVID. Antioxidants (Basel) 2022; 11: 954.
[185] Rathore FA, Khalil MT and Khan OJ. Rehabilitation perspectives in long COVID-19. J Pak Med Assoc 2023; 73: 1553-1555.
[186] Galluzzo V, Zazzara MB, Ciciarello F, Tosato M, Bizzarro A, Paglionico A, Varriano V, Gremese E, Calvani R and Landi F; Gemelli against COVID-19 Post-Acute Care Team. Use of first-line oral analgesics during and after COVID-19: results from a survey on a sample of Italian 696 COVID-19 survivors with post-acute symptoms. J Clin Med 2023; 12: 2992.
[187] Ripani U, Bisaccia M and Meccariello L. Dexamethasone and nutraceutical therapy can reduce the myalgia due to COVID-19 - a systemic review of the active substances that can reduce the expression of interlukin-6. Med Arch 2022; 76: 66-71.
[188] Sarzi-Puttini P, Giorgi V, Marotto D and Atzeni F. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol 2020; 16: 645-660.
[189] Pektas S, Gursoy C and Demirbilek SG. The use of pregabalin in intensive care unit in the treatment of Covid-19-related pain and cough. J Coll Physicians Surg Pak 2021; 31: 143.
[190] Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z and Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet 2019; 393: 768-777.
[191] Vertigan AE, Kapela SL, Ryan NM, Birring SS, McElduff P and Gibson PG. Pregabalin and speech pathology combination therapy for refractory chronic cough: a randomized controlled trial. Chest 2016; 149: 639-648.
[192] Aksan F, Nelson EA and Swedish KA. A COVID-19 patient with intense burning pain. J Neurovirol 2020; 26: 800-801.
[193] Ravagnan G, De Filippis A, Cartenì M, De Maria S, Cozza V, Petrazzuolo M, Tufano MA and Donnarumma G. Polydatin, a natural precursor of resveratrol, induces β-defensin production and reduces inflammatory response. Inflammation 2013; 36: 26-34.
[194] Cardinali DP, Brown GM and Pandi-Perumal SR. Possible application of melatonin in long COVID. Biomolecules 2022; 12: 1646.
[195] Galano A, Tan DX and Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
[196] Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF and O'Garra A. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001; 167: 4974-4980.
[197] Fawaz L, Mrad MF, Kazan JM, Sayegh S, Akika R and Khoury SJ. Comparative effect of 25(OH) D3 and 1,25(OH)2D3 on Th17 cell differentiation. Clin Immunol 2016; 166-167: 59-71.
[198] Ranisavljev M, Todorovic N, Ostojic J and Ostojic SM. Reduced tissue creatine levels in patients with long COVID-19: a cross-sectional study. J Postgrad Med 2023; 69: 162-163.
[199] Liu Q, Mak JWY, Su Q, Yeoh YK, Lui GC, Ng SSS, Zhang F, Li AYL, Lu W, Hui DS, Chan PK, Chan FKL and Ng SC. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut 2022; 71: 544-552.
[200] Zhang L, Xu Z, Mak JWY, Chow KM, Lui G, Li TCM, Wong CK, Chan PKS, Ching JYL, Fujiwara Y, Chan FKL and Ng SC. Gut microbiota-derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID-19: an open-label pilot study. J Gastroenterol Hepatol 2022; 37: 823-831.
[201] Lau RI, Su Q, Lau ISF, Ching JYL, Wong MCS, Lau LHS, Tun HM, Mok CKP, Chau SWH, Tse YK, Cheung CP, Li MKT, Yeung GTY, Cheong PK, Chan FKL and Ng SC. A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 2024; 24: 256-265.
[202] Zha M, Chaffee K and Alsarraj J. Trigger point injections and dry needling can be effective in treating long COVID syndrome-related myalgia: a case report. J Med Case Rep 2022; 16: 31.
[203] Galluzzo V, Zazzara MB, Ciciarello F, Tosato M, Martone AM, Pais C, Savera G, Calvani R, Picca

A, Marzetti E and Landi F; On Behalf Of Gemelli Against Covid-Post-Acute Care Team. Inadequate physical activity is associated with worse physical function in a sample of COVID-19 survivors with post-acute symptoms. J Clin Med 2023; 12: 2517.

[204] Bouzigon R, Dupuy O, Tiemessen I, De Nardi M, Bernard JP, Mihailovic T, Theurot D, Miller ED, Lombardi G and Dugué BM. Cryostimulation for post-exercise recovery in athletes: a consensus and position paper. Front Sports Act Living 2021; 3: 688828.

[205] Gobbi M, Trotti G, Tanzi M, Kasap F, Piterà P and Capodaglio P. Post-COVID symptoms and whole-body cryotheraphy: a case report. J Rehabil Med Clin Commun 2022; 5: 1000075.

[206] Louis J, Theurot D, Filliard JR, Volondat M, Dugué B and Dupuy O. The use of whole-body cryotherapy: time- and dose-response investigation on circulating blood catecholamines and heart rate variability. Eur J Appl Physiol 2020; 120: 1733-1743.

[207] Capodaglio P, Cremascoli R, Piterà P and Fontana JM. Whole-body cryostimulation: a rehabilitation booster. J Rehabil Med Clin Commun 2022; 5: 2810.

[208] Contreras-Briceño F, Espinosa-Ramírez M, Rozenberg D and Reid WD. Eccentric training in pulmonary rehabilitation of post-COVID-19 patients: an alternative for improving the functional capacity, inflammation, and oxidative stress. Biology (Basel) 2022; 11: 1446.